[{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Launches Icatibant Injection to Treat Acute Attacks of Hereditary Angioedema in Adults","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz Launches Generic Icatibant in U.S for Angioedema, Strategically Enhancing Injectables Portfolio","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Icatibant Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Slayback Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Slayback Pharma \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Slayback P.."},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quantum Leap concludes Icatibant Portion of I-SPY COVID Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Quantum Leap Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Le.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Receives USFDA Approval for Icatibant Injection, 30 mg\/3 mL (10 mg\/mL) Single-Dose Prefilled Syringe","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cycle Pharmaceuticals Launches SAJAZIRTM (icatibant) Injection, A New Treatment Option in Hereditary Angioedema (HAE)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Cycle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cycle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cycle Phar.."},{"orgOrder":0,"company":"Adalvo","sponsor":"AmbioPharm","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adalvo Announces Successful DCP Closure for Icatibant","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Adalvo","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adalvo \/ AmbioPharm","highestDevelopmentStatusID":"12","companyTruncated":"Adalvo \/ A.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Pharma Gets U.S. FDA nod for Generic Icatibant Injection","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Icatibant Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharma gets USFDA nod for generic injection to treat hereditary angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Icatibant Acetate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."}]

Find Clinical Drug Pipeline Developments & Deals for Icatibant

Icatibant
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

Icatibant

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

26 API Suppliers, 15 USDMF, 1 JDMF, 2 EU WC, 12 NDC API, 18 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

8 Drugs in Development

8 Drugs in Development

INTERMEDIATES

1 API Suppliers

1 API Suppliers

FINISHED DOSAGE FORMULATIONS

24 FDF Dossiers, 11 FDA Orange Book, 5 Europe, 1 Canada, 3 Australia, 1 South Africa, 3 Listed Dossiers

RELATED EXCIPIENT COMPANIES

2 Actylis

2 Actylis

DIGITAL CONTENT

3 DATA COMPILATION #PharmaFlow, 24 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 4 Finished Drug Prices, 7 Annual Reports

MARKET PLACE

2 APIs

2 APIs

PATENTS & EXCLUSIVITIES

1 Health Canada Patents

1 Health Canada Patents

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Alembic Pharmaceuticals Limited

India

Formnext Forum

Not Confirmed

02

Aurobindo Pharma Limited

India

Formnext Forum

Not Confirmed

03

Cycle Pharmaceuticals

United Kingdom

Formnext Forum

Not Confirmed

04

Adalvo

U.S.A

Formnext Forum

Not Confirmed

05

Glenmark Pharmaceuticals

India

Formnext Forum

Not Confirmed

06

Quantum Leap Healthcare

U.S.A

Formnext Forum

Not Confirmed

07

Slayback Pharma

U.S.A

Formnext Forum

Not Confirmed

08

Fresenius Kabi AG

Germany

Formnext Forum

Not Confirmed